SCHEMBL13289304

SCHEMBL13289304

Bc1cnn2c(NCc3cccc(NC(=O)Nc4cccc(OC)c4)c3)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 4/20 0.48
▸ GSK3B P49841 3/20 0.48
▸ HIF1A Q16665 1/20 0.46
▸ PTGER3 P43115 3/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ EPHB4 P54760 1/20 0.42
▸ AURKA O14965 1/20 0.42
▸ PDPK1 O15530 1/20 0.42
▸ RPS6KB1 P23443 1/20 0.42
▸ RET P07949 1/20 0.42
▸ KDR P35968 1/20 0.42
▸ MAPT P10636 3/20 0.41
▸ ROCK2 O75116 1/20 0.41
▸ ROCK1 Q13464 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13289345 0.96 GSK3B (0.47) CDK2GSK3BHIF1APTGER3MEN1
SCHEMBL13289534 0.95 RET (0.48) CDK2GSK3BHIF1ARETKDR
SCHEMBL13289254 0.92 CDK2 (0.47) CDK2GSK3BMEN1KMT2AEPHB4
SCHEMBL13121757 0.92 CDK2 (0.60) CDK2GSK3BHIF1AALDH1A1RAB9A
SCHEMBL13289713 0.91 CDK2 (0.47) CDK2GSK3BMEN1KMT2AALDH1A1
SCHEMBL13289563 0.90 CDK2 (0.50) CDK2GSK3BPTGER3MEN1KMT2A
SCHEMBL13289130 0.89 RET (0.48) CDK2GSK3BMEN1KMT2AAURKA
SCHEMBL13289322 0.89 GSK3B (0.46) CDK2GSK3BPTGER3KMT2AALDH1A1
SCHEMBL13289245 0.89 CDK2 (0.49) CDK2GSK3BMEN1KMT2AALDH1A1
SCHEMBL12954120 0.89 CDK2 (0.49) CDK2GSK3BEPHB4AURKARPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback